U.S. patent application number 10/961875 was filed with the patent office on 2005-05-12 for quick disintegrating tablet in buccal cavity and production process thereof.
This patent application is currently assigned to Yamanouchi Pharmaceutical Co., Ltd.. Invention is credited to Kajiyama, Atsushi, Masuda, Yoshinori, Mizumoto, Takao, Nyshadham, Janaki Ram, Yanagisawa, Masahiro.
Application Number | 20050100598 10/961875 |
Document ID | / |
Family ID | 22146068 |
Filed Date | 2005-05-12 |
United States Patent
Application |
20050100598 |
Kind Code |
A1 |
Mizumoto, Takao ; et
al. |
May 12, 2005 |
Quick disintegrating tablet in buccal cavity and production process
thereof
Abstract
The present invention relates to a quick disintegrating tablet
in buccal cavity, comprising: a mixture, comprising a drug, a sugar
(A), and an amorphous sugar (B), and after it is forming a tablet,
it is humidified and dried. In particularly, the present invention
relates to a quick disintegrating tablet in buccal cavity
comprising: a mixture; comprising a drug, a sugar (A), and an
amorphous sugar (B) which an amorphous-forming sugar in crystalline
state is dissolved in a medicinally permitted solvent, the
amorphous sugar is obtained from this solution by removing the
solvent, and after it is forming a tablet, and it is humidified and
dried. The tablet in the present invention is to provide stability
against moisture at preserved, because the amorphous sugar changed
to the crystalline state in a nonreversible reaction after it is
humidified and dried in a manufacturing process. The tablet in the
present invention is to further provide a design for the
pharmaceutical preparation with respect to the stability of a drug,
because the tablet is manufactured by one kind of a sugar and an
amorphous sugar. Furthermore, the tablet in the present invention
is to provide a production process by utilizing a common
granulating machine and by utilizing a common tablet machine.
Inventors: |
Mizumoto, Takao; (Shizuoka,
JP) ; Masuda, Yoshinori; (Shizuoka, JP) ;
Kajiyama, Atsushi; (Shizuoka, JP) ; Yanagisawa,
Masahiro; (Shizuoka, JP) ; Nyshadham, Janaki Ram;
(Palo Alto, CA) |
Correspondence
Address: |
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO
CA
94111-3834
US
|
Assignee: |
Yamanouchi Pharmaceutical Co.,
Ltd.
Norman
OK
Yamanouchi Pharma Technologies, Inc.
|
Family ID: |
22146068 |
Appl. No.: |
10/961875 |
Filed: |
October 7, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10961875 |
Oct 7, 2004 |
|
|
|
10453422 |
Jun 2, 2003 |
|
|
|
6803054 |
|
|
|
|
10453422 |
Jun 2, 2003 |
|
|
|
09646249 |
Sep 14, 2000 |
|
|
|
6589554 |
|
|
|
|
09646249 |
Sep 14, 2000 |
|
|
|
PCT/JP98/04592 |
Oct 13, 1998 |
|
|
|
60078761 |
Mar 16, 1998 |
|
|
|
Current U.S.
Class: |
424/464 |
Current CPC
Class: |
A61K 9/2018 20130101;
H04L 67/26 20130101; H04L 69/08 20130101; H04L 12/44 20130101; H04L
69/329 20130101; H04L 29/06 20130101; A61K 9/2095 20130101; A61K
9/0056 20130101; H04L 67/12 20130101 |
Class at
Publication: |
424/464 |
International
Class: |
A61K 009/20 |
Claims
1. A quick disintegrating tablet in buccal cavity, comprising: a
mixture, comprising: a drug; a sugar (A); and an amorphous sugar
(B); and after forming a tablet, it being humidified and dried.
2. The quick disintegrating tablet in buccal cavity according to
claim 1, comprising: a mixture, comprising: a drug; a sugar (A);
and an amorphous sugar (B) which can be obtained by dissolving a
crystalline sugar capable of becoming amorphous in a medicinally
permitted solvent and removing said solvent from said solution and
drying; and after forming a tablet, it being humidified and
dried.
3. The quick disintegrating tablet in buccal cavity according to
claim 1, comprising: a mixture, comprising: a drug; a sugar (A);
and an amorphous sugar (B) which can be obtained by dissolving a
crystalline sugar capable of becoming amorphous in a medicinal
permitted solvent and spray-drying said solution; in which, after
forming a tablet, said tablet being humidified and dried.
4. The quick disintegrating tablet in buccal cavity according to
claim 1, comprising: a crystalline sugar capable of becoming
amorphous is dissolved in a medicinally permitted solvent; said
solution is sprayed on a drug and/or a sugar (A) to coat and/or
granulate, and after forming a tablet, it is humidified and
dried.
5. The quick disintegrating tablet in buccal cavity according to
claim 1 wherein said drug is present in an amount effective to cure
a patient, wherein said amorphous sugar (B) is not less than 2
weight/weight % per preparation weight, and wherein said sugar (A)
is in an amount of the total 100 w/w % of the preparation
consisting essentially of the drug, the sugar (A) and the amorphous
sugar (B).
6. The quick disintegrating tablet in buccal cavity according to
claim 1 wherein the condition for humidification is performed at
not less than an apparent critical relative humidity of a mixture
consisting of a drug, a sugar (A), and an amorphous sugar (B).
7. The quick disintegrating tablet in buccal cavity according to
claim 1 wherein the condition for humidity is 30 to 100 RH %, and
wherein said condition is 15 to 50.degree. C.
8. The quick disintegrating tablet in buccal cavity according to
claim 1 wherein said amorphous sugar (B) is obtained by
lyophilization and/or various granulating methods.
9. A quick disintegrating tablet made by a dry blend granulation
production process comprising the following steps: (i) mixing a
blend comprising at least one saccharide, wherein the saccharide is
at least about 1-90% by volume of the dry blend; (ii) compressing
the mixed dry blend form step (i) into a tablet form; (iii)
humidifying the tablet by exposing the product of step (ii) to a
humidified environment; and (iv) drying the tablet humidified in
step (iii), wherein the hardness of the dried tablet is greater
than that of the compressed tablet of step (ii).
Description
TECHNICAL FEILD
[0001] The present invention relates to a quick disintegrating
tablet in buccal cavity and production process thereof.
BACKGROUND OF THE INVENTION
[0002] As for the pharmaceutical dosage forms for oral use, a
tablet, a capsule, a granule, a powder and the like are mentioned.
However, these dosage forms will have some issues if a patient
takes them. For instance, regarding a tablet or a capsule, if the
patient is a person of advanced age or a child, there are some
cases that they dislike to take the pharmaceutical preparation
because it is difficult for them to swallow it or the preparation
will stick in the throat or the esophagus of them. In addition,
regarding a granule or a powder, in some cases they dislike to take
the preparation under the reason that it is difficult for them to
swallow it with its remaining in buccal cavity or the reason that
they will choke when taking the dosage. Since a compliance to take
the pharmaceutical preparation is caused to fall in these cases, it
is desired to take easily the pharmaceutical dosage forms, and as a
result a disintegrating preparation in buccal cavity has been
studied and developed.
[0003] For instance, "Zydis.RTM." has been developed up to the
product by R. P. Schere Corp. However, since this preparation is
produced by means of lyophilization method, a special manufacturing
equipment such as a lyophilization machine is needed. Additionally,
this preparation cannot be taken over from the pocket of PTP,
"Press Through Package", under the reason that the tablet strength
is small. Furthermore, it is so difficult for the aged to take out
the preparation from package that it is not satisfied with the
aged.
[0004] Several quick disintegrating tablets in buccal cavity, which
is manufactured by means not of lyophilization method but of
tableting method, have been reported. For instance, JP 6-218028-A
(Corresponding to EP 590,963) discloses a quick disintegrating
tablet in buccal cavity which is manufactured by compressing the
moisturized powder being mixed with a drug, an excipient, a binder
agent and the like using water or the like, afterwards by drying
the compression molding. However, it is necessary to have a special
tableting machine spraying a fluidizer on the surface of a tablet
before compression for the avoidance of the issues at the
compression molding. JP 5-271054-A (corresponding to EP 553,777)
discloses a quick disintegrating tablet in buccal cavity which is
manufactured by compressing the mixture comprising a drug, a sugar
and water which is added so much as to moisture said sugar at low
compression pressure, and by drying said tablet. WO93/15724
(corresponding to EP 627,218) also discloses a quick disintegrating
tablet, which is manufactured by compression with humidification
and drying. However, there are some issues in these methods, for
instance, a sticking at compressing with moisture.
[0005] In addition, WO95/20380 (corresponding to U.S. Pat. No.
5,576,014) discloses a quick disintegrating tablet in buccal cavity
in which the invention has been made by one of the present
inventors. This tablet is manufactured by means that a small
moldability sugar is granulated by a high moldability sugar and
afterwards that these granules are compressed by an ordinal
tableting machine. It is thought that there is little trouble in
practice by this production method, however, it is necessary to
utilize at least two kinds of sugars, if there is a case that there
is a restriction to a kind of sugar added, for the counter action
between a drug and said sugar (for example, degradation of drug).
Therefore, a new quick disintegrating tablet in buccal cavity and
production process thereof are desired even at this present, for
instance, this tablet is manufactured and to obtain by using one
kind of sugars.
[0006] Furthermore, regarding a quick disintegrating tablet in
buccal cavity, a patent application or an article discloses the
following production process proposed.
[0007] For instance, JP 9-48726-A discloses the method which a
composition of the mixture consisting of a drug, a sugar and/or
hydrophilic polymer is taken into a molding, and the mixture is
compressed at low compression pressure, and the molding is under
humidification and drying. However, this method is to improve the
strength of tablet surface in particular by moisture of
water-soluble polymer, it is possible to introduce the adhesion
between tablets.
[0008] A method that a mixture consisting of an amorphous sucrose
which is obtained by lyophilization method utilizing a sucrose
solution, a drug and mannitol is molded into a tablet by a rotally
tableting machine, and the obtained tablet is preserved under the
controlled circumstance (at 25.degree. C., 34% RH) is proposed
(abstract of the 13th Japan pharmacological pharmacy, p. 113,
published Mar. 5, 1998). However, a sugar is an amorphous sugar
that is manufactured in further detail by lyophilization method,
but sugars outsides sucrose is not described in the article.
DISCLOSURE OF THE INVENTION
[0009] An object of the present invention is to provide a quick
disintegrating tablet in buccal cavity and production thereof in
which tablets are manufactured with the normal granulator and
tablet machine, with tablet strength being heightened to make a
more stable formulation.
[0010] The present inventors examined the physiological
characterization of sugar in a result to find that a kind of sugars
can be changed to an amorphous state when the sugar solution is
spray-dried, or the sugar solution is used in granulation as a
binding agent. The present inventors further investigated to find
that when an amorphous sugar was treated under humidification and
drying, the tablet strength was increased by changing the amorphous
sugar to a crystal state and that a disintegrating preparation in
buccal cavity with the desired tablet strength was obtained and
have completed the present invention.
[0011] That is, the present invention relates to a quick
disintegrating tablet in the buccal cavity, comprising: a drug, a
sugar (A), and an amorphous sugar (B), in which, after forming the
tablet, it is humidified and dried. In more detail, the present
invention relates to a quick disintegrating tablet in the buccal
cavity, comprising: a mixture, comprising: a drug, a sugar (A), and
an amorphous sugar (B) which is obtained by dissolving a
crystalline sugar capable of becoming amorphous in a medicinally
permitted solvent and then removing the solvent from the solution
and drying, in which after forming the tablet, it is humidified and
then dried. Furthermore, the present invention relates to a quick
disintegrating tablet in the buccal cavity, comprising: a mixture,
comprising: a drug, a sugar (A), and an amorphous sugar (B) which
is obtained by dissolving a crystalline sugar capable of becoming
amorphous in a medicinally permitted solvent, and the solution is
then sprayed and dried, and after forming the tablets, it is
humidified and then dried. In particular, the present invention
relates to a quick disintegrating tablet in buccal cavity,
comprising: a crystalline sugar capable of becoming amorphous is
dissolved in a medicinally permitted solvent; the solution is
sprayed on a drug and/or a sugar (A) to coat and/or granulate; and
after forming a tablet, it is humidified and dried.
[0012] For the drug to be used in the present invention, there are
no particular limitations as long as it is a substance which is
used as a pharmaceutical active ingredient. Examples of
pharmaceutical active ingredients include: sedative hypnotics,
sleep inducers, anti-anxiety drugs, anti-epileptics,
anti-depressants, anti-Parkinson drugs, psychoneural drugs, drugs
acting on the central nervous system, local anesthetics, skeletal
muscle relaxants, autonomic nervous system drugs, anti-fever
analgesics anti-inflammatory drugs, anti-convulsants,
anti-vertigenous drugs, cardiac drugs, drugs for arrhythmia,
diuretics, blood pressure lowering drugs, vasoconstrictors,
vasodilators, drugs for circulatory organs, hyperlipidemia drugs,
respiratory stimulant, anti-tussive, expectorants, anti-tussive
expectorants, bronchodilators, stegnotic, peptic ulcer drugs,
stomach digestive drugs, antacids, laxatives, choleretics, drugs
for the digestive tract, adrenal hormone drugs, hormone drugs,
urinary tract drugs, vitamins, hemostatic drugs, liver drugs, gout
treatment drugs, drugs for diabetes, anti-histamines, antibiotics,
antibacterial agents, anti-malignant tumor drugs, chemotherapy
drugs, multi-purpose cold medicines, tonic medicines, osteoporosis
drugs, and the like. There are no particular limitations on the
amount of these drugs to be mixed as long as it is the usual
effective treatment amount. It should be around 50 weight/weight %
or below of the entire tablet, and is preferably 20 weight/weight %
or below.
[0013] In case that the present invention is applied to a drug
having unpleasant taste, the drug is preferred to be treated in a
preferably taste masking method (for instance, WO92/09275).
[0014] In case of that the present invention is performed for a
drug desired to be sustained, the drug is preferred to be treated
in a preferably sustained-release method (for instance,
CA2038400-0), to obtain a particle which is controlled a drug
release in a known manner in itself.
[0015] Furthermore, the preparation of the present invention can be
also applied to a drug which is needed to be absorbed through a
membrane of buccal cavity, since the preparation of the present
invention is taken by a patient with disintegrating and dissolving
in buccal cavity.
[0016] There are no particular limitations on sugar (A) which is to
be used in the present invention as long as it is one which is
normally medicinally permitted. Sugar (A) is preferably a sugar or
sugar-alcohol which dissolves in the mouth. Examples include
lactose, glucose, trehalose, mannitol, erythritol, and the like.
Sugar (A) can be one type or two or more types combined.
Furthermore, since sugar (A) functions as an excipient which
dissolves inside the buccal cavity, the amount of sugar (A) to be
added to the quick disintegrating tablet of the present invention
is not particularly limited as long as it is an effective amount in
order to achieve this function in the quick disintegrating tablet.
The amount of sugar (A) to be added is dependent on the amount of
drug and can be adjusted appropriately. In other words, when the
amount of drug is small, the amount of sugar (A) to be added
becomes large, and if the amount of drug is large, the amount of
sugar (A) to be added becomes small. The amount of sugar (A) to be
added is also dependent on the size of the tablet. The amount of
sugar (A) can be adjusted as a ratio with the other excipients.
[0017] The "amorphous sugar (B)" of the present invention signifies
a sugar which is medicinally usually permitted and which is
amorphous or which is capable of becoming amorphous. For example,
an amorphous sugar (B) can be obtained by dissolving a crystalline
sugar capable of becoming amorphous in a medicinally permitted
solvent such as water and alcohol and the like, and then obtained
by removing the solvent from this solution, and drying. There are
no particular limitations for the method of removing the solvent as
long as it is a method normally implemented in the pharmaceutical
manufacturing process. For example, these methods include spray
drying method, freeze-drying method, or various granulating methods
such as fluidized-bed granulating method, vertical granulating
method, tumbling granulating method. From a production standpoint,
spray drying method or the various granulating methods are
preferred. Among the various granulating methods, a method is
preferred wherein: a crystalline sugar capable of becoming
amorphous in a medicinally permitted solvent such as water,
alcohol, and the like; this is used as a binding agent; this
becomes amorphous when it is sprayed by a twin fluid nozzle and
coats and/or granulates the drug and/or the sugar. Here, a
crystalline sugar capable of becoming amorphous can be dissolved in
a medicinally permitted solvent. This solution can be sprayed
against the drug and/or the sugar (A), and they can be coated and
granulated with an amorphous sugar (B). Examples of amorphous
sugars (B) include glucose, lactose, maltose, sorbitol, trehalose,
lactitol, fructose, and the like. This amorphous sugar (B) can be
of one type or be a combination of two or more types. In the
present invention, "amorphous sugar" signifies a sugar which is
materially amorphous or which is capable of becoming amorphous. In
the process of becoming amorphous, the present invention also
includes states where a portion is not amorphous. The amount of
amorphous sugar (B) to be added is 2-20 weight/weight % with
respect to the previous sugar (A), or 2-20 weight/weight % of the
entire tablet.
[0018] As for the advantage for utilizing an amorphous sugar in the
present invention, it is easy to increase tablet strength by steps
of humidification and drying. Since an amorphous sugar has a low
critical moisture, the tablet can be treated at the low moisture
level such that an amorphous sugar can adsorb. In addition, the
moisture absorbed in a humidification process dissolve a part of
surface of sugar particles around, afterwards in a drying process,
the tablet strength can increase because of the re-attachment of
between sugar particles. On the other hand, to the contrally to the
present invention, it is easily to be predicted that the production
process has some difficulties, for instance, in case that the sugar
consists of sugars in a crystalline state, since the sufficient
moisture adsorption will not happen at a low humidification
condition, the tablet strength will not increase, in case at a high
humidification condition, the adhesion of between tablets will
happen and it is easily predictable for actual manufacturing to
have difficulty.
[0019] As for the other advantage for utilizing amorphous sugar in
the present invention, since a sugar in amorphous state is changed
to a crystalline state in a humidification and drying process
unreversibly, a dried tablet has a high critical moisture point. As
a result, said tablet can maintain a tablet strength against the
moisture in the stored condition. Furthermore, since one kind of
sugar consisting of crystalline state and amorphous state can
manufacture a quick disintegrating tablet in buccal cavity to avoid
a restriction for choosing a sugar which do not happen the changes
against a drug.
[0020] In the present invention, "forming" signifies forming into a
tablet or the like with a pressure equal to or greater than the
pressure required to maintain the desired shape. In the forming
process, a normal tablet machines can be used. Examples include a
single tablet machine or rotary tablet machine.
[0021] In the present invention, "humidifying", when implemented in
combination with the next step of drying, is for increasing the
tablet strength, the humidifying conditions being determined by the
apparent critical relative humidity of the mixture of a drug, a
sugar (A), an amorphous sugar (B), and signifies increasing the
humidity to greater than or equal to the critical relative humidity
of this mixture. For example, the humidity is 30-100 RH %, and is
preferably 50-90 RH %. At this time, temperature is 15-50.degree.
C., and preferably 20-40.degree. C. The point of the humidifying
process of the present invention is to convert sugar in the
amorphous state to a crystalline state, to heighten the tablet
strength, and to make the tablet more stable.
[0022] In the present invention, "drying" is implemented in order
to remove the water absorbed by the humidifying the amorphous
sugar. There are no particular limitations for the drying
conditions as long as they are the usual conditions for removing
water content. For example, it should be 10-100.degree. C. and is
preferably 20-60.degree. C.
[0023] The quick disintegrating tablet in buccal cavity can contain
various medicinally permitted excipients such as disintegrating
agents, stabilization agents, binding agents, diluting agents,
lubricating agents, and the like.
[0024] The production method of the quick disintegrating tablet in
buccal cavity is described below.
[0025] For the production method of the present invention, a drug,
a sugar (A), and an amorphous sugar (B) are mixed, and after
forming the mixture into a tablet, it is humidified and dried. In
more detail, in the production method of the present invention, a
mixture of the following is formed: a drug, a sugar (A), and an
amorphous sugar (B) which is obtainable by dissolving a crystalline
sugar capable of becoming amorphous in a medicinally permitted
solvent and removing the solvent from the solution and drying, and
the tablet is humidified and dried. Furthermore, in the production
method of the present invention, a mixture of the following is
formed into a tablet: a drug, a sugar (A), and an amorphous sugar
(B) which is obtainable by dissolving a crystalline sugar capable
of becoming amorphous in a medicinally permitted solvent and
spraying and drying the solution, and the tablet is humidified and
dried. In particular, in the production method of the present
invention, after dissolving a crystalline sugar capable of becoming
amorphous in a medicinally permitted solvent and by using a binding
agent, the solution is sprayed with a twin fluid nozzle or the like
against a drug and/or sugar (A), and after forming a coated product
and/or granulated product by coating and/or granulating with an
amorphous sugar (B), and after forming a tablet, it is humidified
and dried.
[0026] Here, the definitions and the preferred embodiments of the
"drug", "sugar (A), and "amorphous sugar (B)", as well as the
processing steps for the production of quick disintegrating tablet
in buccal cavity including "forming", "humidifying", and "drying"
are described previously.
[0027] Furthermore, as a method for removing the solvent in the
present invention, there are no particular limitations as long as
it is a method implemented in the normal manufacturing process. For
this method, examples include spray drying method, freeze-drying
method, or various granulating methods such as fluidized-bed
granulating method, vertical granulating method, tumbling
granulating method, or the like. From the standpoint of production,
the spray drying method or the various granulating methods are
preferred. Among these, in the various granulating methods, a
method is preferred, wherein: a crystalline sugar capable of
becoming amorphous and which is dissolved in a medicinally
permitted solvent such as water or alcohol is used as a binding
agent, and it becomes amorphous when spraying and coating or
granulating with a twin fluid nozzle or the like against drug
and/or sugar (A). Here, crystalline sugar which is capable of
becoming amorphous can be dissolved in a medicinally permitted
silvent, and the solution can be sprayed, and the drug and/or sugar
(A) can be coated and granulated with amorphous sugar (B).
[0028] In the production method of the present invention, various
medicinally permitted excipients such as disintegrating agents,
stabilizing agents, binding agents, diluents, lubricants, or the
like can be added to any of the production steps.
BREIF DESCRIPTION OF DRAWINGS
[0029] FIG. 1 shows the stability of the tablet strength in the
present invention. In the figure, the horizontal axis represents to
time and the vertical axis represents to tablet strength.
BEST MODE FOR CARRYING OUT THE INVENTION
[0030] The present invention will be explained further by citing
examples. The present invention is not limited to these
embodiments. Furthermore, regarding the tablet of the present
invention, the tablet strength and time of disintegration in the
buccal cavity have been evaluated. Because it is considered to have
little influence on the evaluation categories, the drug is not
always included.
EXAMPLE 1
[0031] Mannitol 602 g and lactose 602 g were mixed. This was passed
through a sieve (14 mesh). 433 g of glucose solution (15 w/v %) was
used as a binding agent for this mixture, and the mixture was
granulated in a fluidized-bed granulator. Up to 157 g of the
solution was used to coat the above mixture at a spray pressure of
2.5 kg/cm.sup.2. Afterwards, it was granulated with spray pressure
1.5 kg/cm.sup.2. After drying the granule, peppermint flavor 10g,
stearic acid 12g, magnesium stearate 10g were combined. Rotary
tablet machine was used to manufacture tablets which were 540 mg
per one tablet (tablet hardness 1.4 kp (n=5)). Next, this tablet
was humidified and heated for 20 minutes in a thermo-hygrostat at
35.degree. C., 85% RH. Afterwards, it was dried for 15 minutes at
50.degree. C. (humidity 30%), and the tablet of the present
invention was achieved. The obtained tablet had hardness of 9.1 kp,
and buccal cavity disintegrating time of 17 seconds.
EXAMPLE 2
[0032] 175 g of a lactose solution (10 w/v %) was a binding agent
for 350 g of lactose (Domo milk Corp.). This was granulated in a
fluidized-bed granulator (Ohkawara Seisakusho). Up to 70 g of the
previous solution was used to coat the lactose with a spray
pressure of 2.5 kg/cm.sup.2. Afterwards, it was granulated with a
spray pressure 1 kg/cm.sup.2. After drying the granule, 0.5%
magnesium stearate was mixed with the granule. Tablets ((phi 10 mm,
10 mmR), tablet hardness 2.3 kp (n=5)) of 300 mg per tablet were
produced using a rotary tablet machine. Next, the tablet was stored
under heated humidified conditions of 25.degree. C./70% RH for 19
hours, using a thermo-hygrostat (Tabiespec Corp., PR-35C).
Afterwards it was dried for 2 hours at 25.degree. C. (humidity
50%). The tablet of the present invention was obtained. The
obtained tablet had a hardness of 4.1 kp (n=5) and a buccal cavity
disintegration time of 20 seconds.
EXAMPLE 3
[0033] 378 g of mannitol (Towa Chemical Industry Corp.) was passed
through a sieve (20 mesh). Afterwards, this was granulated in a
fluidized bed granulator (Ohkawara Seisakusho) with 133 g of an
aqueous solution of hydrated crystalline glucose (Nippon Shokuhin
Kako Corp.) (15 w/v %) as a binding agent. Up to 50 g of the
previous solution was used to coat the mannitol with a spray
pressure of 2.5 kg/cm.sup.2. Afterwards, it was granulated with a
spray pressure 1.5 kg/cm.sup.2. At this time, the disappearance of
the absorption peak derived from glucose crystals (i.e. glucose is
amorphous) was confirmed using a differential scanning calorimeter
(DSC for short). 0.5% magnesium stearate was mixed with the
granule. Tablets ((phi 8 mm, 9.6 mmR), tablet hardness 2.0 kp
(n=5)) of 150 mg per tablet were produced using a rotary tablet
machine with a compression pressure of approximately 0.18
ton/punch. Next, the tablet was stored under heated humidified
conditions of 25.degree. C./70% RH for 24 hours, using a
thermo-hygrostat (Tabiespec Corp., PR-35C). Afterwards it was dried
for 2 hours at 30.degree. C. (humidity 40%). The tablet of the
present invention was obtained. The obtained tablet had a hardness
of 5.4 kp (n=5) and a buccal cavity disintegration time of 20
seconds. Furthermore, by measuring the obtained tablet with DSC, it
was confirmed that an absorption peak derived from glucose crystals
was present and glucose had crystallized.
EXAMPLE 4
[0034] 425.25 g of erythritol (Nikken Chemical Corp.) was passed
through a sieve (20 mesh). Afterwards, this was granulated with a
fluidized-bed granulator (Ohkawara Seisakusho) with 150 g of
maltose (Product name Sanmalt-S, Hayashibara Shoji Corp.) aqueous
solution (15 w/v %) as a binding agent. Up to 60 g of the previous
solution was used to coat erythritol with a spray pressure of 3.0
kg/cm.sup.2. Afterwards, it was granulated with a spray pressure
1.4 kg/cm.sup.2. 0.5% magnesium stearate was mixed with the
granule. Tablets ((phi 8 mm, 9.6 mmR), tablet hardness 2.0 kp
(n=5)) of 150 mg per tablet were produced using a rotary tablet
machine with a compression pressure of approximately 0.3 ton/punch.
Next, the tablet was stored under heated humidified conditions of
25.degree. C./70% RH for 24 hours, using a thermo-hygrostat
(Tabiespec Corp., PR-35C). Afterwards, it was dried for 2 hours at
30.degree. C. (humidity 40%). The tablet of the present invention
was obtained. The obtained tablet had a hardness of 7.6 kp (n=5)
and a buccal cavity disintegration time of 20 seconds.
EXAMPLE 5
[0035] 360 g of mannitol (Towa Chemical Industry) was passed
through a sieve (20 mesh). Afterwards, this was granulated in a
fluidized-bed granulator (Ohkawara Seisakusho) with 266 g of
fructose (Hayashibara Shoji Company) aqueous solution (15 w/v %) as
a binding agent. With respect to this granule, it was confirmed by
DSC that the absorption peak derided from fructose crystals
disappeared and the fructose was amorphous. 0.5% magnesium stearate
was mixed with the granule. Tablets ((phi 8 mm, 9.6 mmR), tablet
hardness 1.1 kp (n=5)) of 150 mg per tablet were produced using a
rotary tablet machine with a compression pressure of approximately
0.06 ton/punch. Next, the tablet was stored under heated humidified
conditions of 25.degree. C./70% RH for 12 hours, using a
thermo-hygrostat (Tabaiespec Corp., PR-35C). Afterwards, it was
dried for 2 hours at 40.degree. C. The tablet of the pressure
invention was obtained. The obtained tablet had a hardness of 5.6
kp (n=5) and a buccal cavity disintegration time of 15 seconds.
EXAMPLE 6
[0036] 133 g of a lactitol (Towa Chemical Industry Corp., Milhen)
aqueous solution (15 w/v %) was a binding agent for 380 g of
lactose (Domo milk Corp.). This was granulated with a fluidized-bed
granulator (Ohkawara Seisakusho). With respect to this granule, it
was confirmed by DSC that the absorption peak derived from lactitol
crystals disappeared had the lactitol was amorphous. 0.5% magnesium
stearate was mixed with the granule. Tablets ((phi 8 mm, 9.6 mmR),
tablet hardness 1.0 kp (n=5)) of 150 mg per tablet were produced
using a rotary tablet machine with a compression pressure of
approximately 0.1 ton/punch. Next, the tablet was stored under
heated humidified conditions of 25.degree. C./70% RH for 12 hours,
using a thermo-hygrostat (Tabaiespec Company, PR-35C). Afterwards
it was dried for 2 hours at 40.degree. C. The tablet of the present
invention was obtained. The obtained tablet had a hardness of 3.7
kp (n=5) and a buccal cavity disintegration time of 15 seconds.
Furthermore, by measuring the obtained tablet with DSC, it was
confirmed that an absorption peak derived from lactitol crystals
was present and lactitol had crystallized.
EXAMPLE 7
[0037] 133 g of a trehalose (Hayashibara Shoji) aqueous solution
(15 w/v %) was a binding agent for 380 g of hydrated crystalline
glucose (Nippon Shokuhin). This was granulated with a fluidized-bed
granulator (Ohkawara Seisakusho). 0.5% magnesium stearate was mixed
with the granule. Tablets ((phi 8 mm, 9.6 mmR), tablet hardness 1.0
kp (n=5)) of 150 mg per tablet were produced using a rotary tablet
machine with a compression pressure of approximately 0.1 ton/punch.
Next, the tablet was stored under heated humidified conditions of
25.degree. C./70% RH for 12 hours, using a thermo-hygrostat
(Tabaiespec Cor., PR-35C). Afterwards, it was dried for 2 hours at
40.degree. C. The tablet of the present invention was obtained. The
obtained tablet had a hardness of 4.3 kp (n=5) and a buccal cavity
disintegration time of 20 seconds.
EXAMPLE 8
[0038] 40 g famotidine, 336.8 g of erythritol (Nikken Chemical
Corp.) were passed through a sieve (20 mesh). Afterwards, this was
granulated with a fluidized-bed granulator (Ohkawara Seisakusho)
with 100 g of a lactitol (Towa Chemical Industry Corp.) aqueous
solution (20 w/v %) as a binding agent. 0.8% calcium stearate was
mixed with the granule. Tablets ((phi 8.5 mm, 10.2 mmR), tablet
hardness 1.1 kp (n=5)) of 200 mg per tablet were produced using a
rotary tablet machine with a compression pressure of approximately
0.14 ton/punch. Next, the tablet was stored under heated humidified
conditions of 25.degree. C./80% RH for 12 hours, using a
thermo-hygrostat (Tabaiespec Company, PR-35C). Afterwards, it was
dried for 2 hours at 30.degree. C. (humidity 40%). The tablet of
the present invention was obtained. The obtained tablet had a
hardness of 6.2 kp (n=5) and a buccal cavity disintegration time of
20 seconds.
EXAMPLE 9
[0039] 100 g acetaminophen, 227 g lactose (Domo milk Company) were
passed through a sieve (20 mesh). Afterwards, this was granulated
in a fluidized-bed granulator (Ohkawara Seisakusho) with 100 g of a
trehalose (Hayashibara Shoji) solution (20 w/v %) as a biding
agent. 0.5% magnesium stearate was mixed with the granule. Tablets
((phi 8.5 mm, 10.2 mmR), tablet hardness 1.4 kp (n=5)) of 200 mg
per tablet were produced using a rotary tablet machine with a
compression pressure of approximately 0.3 ton/punch. Next, the
tablet was stored under heated humidified conditions of 25.degree.
C./80% RH for 12 hours, using a thermo-hygrostat (Tabaiespec
Companu, PR-35C). Afterwards, it was dried for 2 hours at
30.degree. C. (humidity 40%). The tablet of the present invention
was obtained. The obtained tablet had a hardness of 3.1 kp (n=5)
and a buccal cavity disintegration time of 25 seconds.
EXAMPLE 10
[0040] An aqueous solution (25 w/v %) of trehalose (Hayashibara
Shoji) was spray dried using a spray dryer (Daiwa Kagaku DL-41). An
amorphous trehalose powder was obtained. 5 parts trehalose powder
to 95 parts mannitol (Towa Chemical Industry Corp.) were mixed in a
mortar. This mixture was made into tablets of one tablet 150 mg
((phi 8 mm, 9.6 mmR), tablet hardness 1.1 kp (n=5)) using an oil
press device. Next, the tablet was stored under heated humidified
conditions of 25.degree. C./80% RH for 12 hours, using a
thermo-hygrostat (Tabaiespec Corp., PR-35C). Afterwards, it was
dried for 2 hours at 30.degree. C. (humidity 40%). The tablet of
the present invention was obtained. The obtained tablet had a
hardness of 6.1 kp (n=5) and a buccal cabity disintegration time of
15 seconds.
EXAMPLE 11
[0041] 380 g of mannitol (Towa Chemical Industry) was passed
through a sieve (20 mesh). Afterwards, this was granulated in a
fluidized-bed granulator (Ohkawara Seisakusho) with 133 g of
trehalose (Hayashibara Shoji Company) aqueous solution (15 w/v %)
as a binding agent. 0.5% magnesium stearate was mixed with the
granule. Tablets ((phi 8 mm, 9.6 mmR), tablet hardness 2.8 kp
(n=5)) of 150 mg per tablet were produced using a rotary tablet
machine with a compression pressure of approximately 0.4 ton/punch.
Next, the tablet was stored under heated humidified conditions of
25.degree. C./70% RH for 12 hours, using a thermo-hygrostat
(Tabaiespec Corp., PR-35C). Afterwards, it was dried for 2 hours at
30.degree. C. (humidity 40%). The tablet of the pressure invention
was obtained. The obtained tablet had a hardness of 3.9 kp
(n=5).
COMPARATIVE EXAMPLE 1
[0042] A sugar (B) is utilized xyritol which does not change into
amorphous state in replacing trehalose in Example 11. In
particularly, 380 g of a mannitol (Towa Chemical Industry Corp.)
was passed through a sieve (20 mesh). Afterwards, this was
granulated in a fluidized-bed granulator (Ohkawara Seisakusho) with
130 g of a xyritol (Towa Chemical Industry Corp.) aqueous solution
(15 w/v %) as a binding agent. With respect to this granule, it was
confirmed by DSC that the absorption peak derided from xyritol
crystals remained and the xyritol was in crystalline state. 0.5%
magnesium stearate was mixed with the granule. This was granulated
with a fluidized-bed granulator (Ohkawara Seisakusho). 0.5%
magnesium stearate was mixed with the granule. Tablets ((phi 8 mm,
9.6 mmR), tablet hardness 3.2 kp (n=5)) of 150 mg per tablet were
produced using a rotary tablet machine with a compression pressure
of approximately 0.8 ton/punch. Next, the tablet was stored under
heated humidified conditions of 25.degree. C./70% RH for 12 hours,
using a thermo-hygrostat (Tabaiespec Cor., PR-35C). Afterwards, it
was dried for 2 hours at 30.degree. C. (humidity 40%). The tablet
of the Comparative Example was obtained. The obtained tablet had a
hardness of 3.5 kp (n=5). In case of utilizing a sugar which did
not change to amorphous state, it was confirmed that a tablet
strength did not show a large increasing by a humidification and
drying process.
[0043] [Experiment 1]
[0044] A stability of the tablet strength at a stored condition in
the present invention was under examination. In the present
experiment, the obtained tablet in Example 11 in the present
invention was examined as the present invention tablet. To the
contrally, regarding the obtained tablet in Comparative Example 1,
the tablet was under a humidification and drying process to obtain
a tablet (Example 1), or the tablet was before a humidification and
drying process (Comparative Example 2). The condition for stored
was at 25.degree. C. (humidity 75%). FIG. 1 shows the result of the
Experiment. FIG. 1 suggested that the preparation in the present
invention has a stability of showing little changes in tablet
strength under the stored at a moisture condition. To the
contrally, it was found that the tablet strength in the Comparative
Examples decreased down to the half of the initial strength by
gradient from the time the experiment started. Therefore, the
present invention is to provide a more stability against the
moisture under the stored.
Industrial Feasibility
[0045] After the tablet of the present invention is processed by
humidification and drying during the production process, the
amorphous sugar irreversibly changes to crystalline state. It is
stable with respect to the storage humidity. The tablet strength
can be maintained in a stable manner. Furthermore, in the tablet of
the present invention, it is possible to produce the sugar and the
amorphous sugar of the present invention from one type of sugar. As
a result, it is possible to design a tablet which takes into
account the stability of the drug. Furthermore, in the tablet of
the present invention, it is possible to provide a production
method which uses the standard granulator and tablet machine.
[0046] In particular, in the production method of the present
invention, wherein: sugar which is capable of becoming amorphous is
dissolved in a medicinally permitted solvent; the solution is
sprayed against drug and/or sugar (A); this is coated and/or
granulated, a freeze dryer is not necessary. The present invention
uses the granulator and tablet machine which is a widely accepted
part tablet forming process. As a result, this is a valuable method
because of its high production effeciency.
* * * * *